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patients did not ﬁ ll in the scale, only 31% greatly improved, 57% improved, 10% did 
not changed and 2% worsened during medical intervention. TBS correlated moder-
ately with clinical judgement of change; 0.749, P < 0.001, and also, linearity was 
observed, with changes at end-of-trial visit in both domains of the OABq-SF; Flineal = 
23.02, P < 0.001 and Flineal = 31.02, P < 0.001. TBS was able to differentiate groups 
of patients with different levels of change in symptoms severity and health-related 
quality of life of the OABq-SF questionnaire; F = 8.09, P < 0.001 and F = 10.5, P < 
0.001, respectively, with effect sizes between 1.69 and −0.44. CONCLUSIONS: The 
Spanish version of TBS scale demonstrated strong validity and responsiveness psycho-
metric properties to be used in the subjective assessment of outcomes related with 
treatment of OAB. 
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OBJECTIVES: Assess the impact of the treatment of urinary disorders of the lower 
urinary tract (LUT) suggestive of benign prostatic hypertrophy (BPH) using medical 
treatment under actual conditions of use. METHODS: A pragmatic cohort of 420 
patients (France, Italy, and Portugal) treated medically, was followed up for 6 months, 
using 3 questionnaires: IPSS, MSF4 and SF12. RESULTS: 366 patients under medical 
treatment were assessed. 267 patients were treated with phytotherapy, versus 80 
patients on “other treatments”. At inclusion, the patients treated with Serenoa repens 
versus “other treatments” were different on the following characteristics: Age (P = 
0.0047), time since diagnosis (p = 0.006), country (P < 0.0001), IPSS score (P = 
0.0087), physical dimension of the SF12 (P = 0.0071). The “change from baseline” 
for the scores of the IPSS and SF12 self-assessment questionnaires between the 2 
treatment groups was comparable. a generalized linear model adjusted for age, time 
since diagnosis, country, IPSS score, and the physical dimension of the SF12 score at 
inclusion was used, making the 2 treatment groups comparable. We observed an 
improvement in the IPSS score from 6 weeks. We were not able to demonstrate a 
signiﬁ cant difference between the 2 treatment groups concerning the “change from 
baseline” of the IPSS score (P = 0.7288). The same applies to the analyses at 3 and 6 
months where the p-values were 0.2047 and 0.0947 respectively. We did not observe 
any statistical difference in the scores for the 2 dimensions of the SF12 between the 
2 treatment groups. CONCLUSIONS: We observed an improvement in the IPSS and 
SF12 scores from 6 weeks. This improvement was not signiﬁ cantly different between 
the 2 treatment groups. Under actual conditions of use, the various medical treatments 
gave similar improvements.
